article Open AccessTop 1% cited
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Annals of the Rheumatic Diseases · 2019 · Vol. 78(6) · pp. 736–745
Antonis Fanouriakis✉(National and Kapodistrian University of Athens)Myrto Kostopoulou(General Hospital of Athens G. Genimatas)Alessia Alunno(University of Perugia)Martin Aringer(Center for Rheumatology)Ingeborg M. Bajema(Leiden University Medical Center)John Boletis(National and Kapodistrian University of Athens)Ricard Cervera(Hospital Clínic de Barcelona)Andrea Doria(University of Padua)Caroline Gordon(University of Birmingham)Marcello Govoni(University of Ferrara)Frédéric Houssiau(Cliniques Universitaires Saint-Luc)David Jayne(Addenbrooke's Hospital)Marios KouloumasAnnegret Kuhn(University Hospital Münster)J.L. Larsen(Rigshospitalet)Kirsten LerstrømGabriella Moroni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)Marta Mosca(University of Pisa)Matthias Schneider(Heinrich Heine University Düsseldorf)Josef S Smolen(Center for Rheumatology)Elisabet Svenungsson(Karolinska University Hospital)Vladimı́r Tesař(Charles University)Anǵela Tincani(Brescia University)Anne Troldborg(Aarhus University Hospital)Ronald van Vollenhoven(Amsterdam University Medical Centers)Joerg Wenzel(University Hospital Bonn)George Βertsias(ENT and Allergy)Dimitrios T. Boumpas(National and Kapodistrian University of Athens)
Systemic Lupus Erythematosus ResearchCytokine Signaling Pathways and InteractionsAutoimmune and Inflammatory Disorders ResearchMedicineBelimumabHydroxychloroquineRituximabAzathioprineIntensive care medicineAntiphospholipid syndromeSystemic lupus erythematosusExpert opinionPrednisone
MeSH terms
Biological ProductsGlucocorticoidsHumansHydroxychloroquineImmunosuppressive AgentsLupus Erythematosus, SystemicSeverity of Illness IndexComorbidityEvidence-Based MedicineDisease Management
Funding
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Biogen
- Celgene
- Incyte
- National and Kapodistrian University of Athens
- European League Against Rheumatism
- Galderma
- LEO Pharma
Citations
1,964
FWCI
189.87
field-weighted impact
References
168
Percentile
100%
vs. same field & year
Citations per year
Cited by
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
Annals of the Rheumatic Diseases · 2020 · 788 citations
References
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Arthritis & Rheumatism · 2012 · 1,404 citations
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
Annals of the Rheumatic Diseases · 2008 · 967 citations
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Arthritis & Rheumatism · 2009 · 1,365 citations
Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
Arthritis & Rheumatism · 2002 · 1,058 citations
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Annals of the Rheumatic Diseases · 2012 · 1,018 citations
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Arthritis & Rheumatism · 2011 · 1,623 citations
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Annals of the Rheumatic Diseases · 2007 · 753 citations
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
Annals of the Rheumatic Diseases · 2016 · 875 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.